The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal

Psychopharmacology

Volumn 192, Issue 3, 2007, Pages 385-396

  Skelton, Kelly H ^a,b   Gutman, David A ^a   Thrivikraman, K V ^a   Nemeroff, Charles B ^a   Owens, Michael J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Anxiety; Benzodiazepines; Corticotropin releasing factor; HPA axis; Stress; Withdrawal

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; BENZODIAZEPINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; FLUMAZENIL; LORAZEPAM; ANXIOLYTIC AGENT; CORTICOTROPIN RELEASING FACTOR RECEPTOR; HETEROGENEOUS NUCLEAR RNA; HYPNOTIC SEDATIVE AGENT; PYRIMIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFECT; DRUG WITHDRAWAL; GENE EXPRESSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; THALAMUS MIDLINE NUCLEUS; WITHDRAWAL SYNDROME; ADDICTION; ANIMAL; ANTERIOR HYPOTHALAMUS; DRUG ANTAGONISM; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; STRESS;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; FLUMAZENIL; GENE EXPRESSION; HYPNOTICS AND SEDATIVES; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LORAZEPAM; MALE; NEURONS; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, HETEROGENEOUS NUCLEAR; STRESS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 34247898953     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0713-3     Document Type: Article

References (58)

1. Adinoff B, Anton R, Linnoila M, Guidotti A, Nemeroff CB, Bissette G (1996) Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmacology 15:288-295
2. Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, Rapoport JL (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51:794-803
3. Baker DG, West SA, Nicholson WE, Ekhator NN, Kasckow JW, Hill KK, Bruce AB, Orth DN, Geracioti TD Jr (1999) Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 156(4):585-588
4. Baldwin HA, Hitchcott PK, File SE (1989) Evidence that the increased anxiety detected in the elevated plus-maze during chlordiazepoxide withdrawal is not due to enhanced noradrenergic activity. Pharmacol Biochem Behav 34:931-933
5. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT (1991) CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 103:227-232
6. Ballenger JC (1991) Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry 52:18-23
7. Basso AM, Spina M, Rivier J, Vale W, Koob GF (1999) Corticotropin- releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology 145 (1):21-30
8. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624-629
9. Britton K, Morgan J, Rivier J, Vale W, Koob GF (1985) Chlordiazepoxide attenuates CRF-induced response suppression in the conflict test. Psychopharmacology 86:170-174
10. 9-41 α helical) reduces morphine withdrawal in rats. Prog Neuro-psychopharmacol Biol Psychiatry 22:775-785
11. Cowley DS, Roy-Byrne PP, Radant A, Ritchie JC, Greenblatt DJ, Nemeroff CB, Hommer DW (1995) Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 12:147-157
12. Dunn AJ, Berridge CW (1990) Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 15:71-100
13. Dunn AJ, File SE (1987) Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm Behav 21:193-202
14. Funada M, Hara C, Wada K (2001) Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system. Eur J Pharmacol 430(2-3):277-281
15. Gawin FH, Kleber HD (1986) Abstinence symptomatology and psychiatric diagnosis in chronic cocaine abusers. Arch Gen Psychiatry 43:107-113
16. Griebel G, Perrault G, Sanger D (1998) Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology 138:55-66
17. 1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 304:874-880
18. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L (1995) Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 6:74-80
19. Heinrichs SC, Min H, Tamraz S, Carmouche M, Boehme SA, Vale WW (1997a) Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22(4):215-224
20. 2, receptors mediate anxiogenic-like behavior. Regulatory Pept 71:15-21
21. Imaki T, Wang XQ, Shibasaki T, Harada S, Chikada N, Takahashi C, Naruse M, Demura H (1995) Chlordiazepoxide attenuates stress-induced activation of neurons, corticotropin-releasing factor (CRF) gene transcription and CRF biosynthesis in the paraventricular nucleus (PVN). Mol Brain Res 32:261-270
22. Imaki T, Naruse M, Harada S, Chikada N, Imaki J, Onodera H, Demura H, Vale W (1996) Corticotropin-releasing factor upregulates its own receptor mRNA in the paraventricular nucleus of the hypothalamus. Brain Res Mol Brain Res 38(1):166-170
23. Institute of Laboratory Animal Resources (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington DC
24. Iredale PA, Alvaro JD, Lee Y, Terwilliger R, Chen YL, Duman RS (2000) Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 74:199-208
25. Kalogeras KT, Calogero AE, Kuribayiashi T, Kahn J, Gallucci WT, Kling MA, Chrousos GP, Gold PW (1990) In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. J Clin Endocrinol Metab 70:1462-1471
26. Keith LD, Crabbe JC, Robertson LM, Young ER (1983) Ethanol dependence and the pituitary adrenal axis in mice. II. Temporal analysis of dependence and withdrawal. Life Sci 33:1889-1897
27. Krulik R, Cerny M (1971) Effects of chlordiazepoxide on stress in rats. Life Sci 10:145-151
28. Liebsch G, Landgraf R, Engelmann P, Lorscher P, Holsboer F (1999) Chronic infusion of CRH1 or CRH2 receptor antisense oligonucleotides into the rat brain differentially affects emotional and stress coping behavior. J Psychiatr Res 33:153-163
29. Lu L, Liu D, Ceng X, Ma L (2000) Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12(12):4398-4404
30. Maj M, Turchan J, Smialowska M, Przewlocka B (2003) Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 37(2):105-110
31. McNally GP, Akil H (2002) Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience 112(3):605-617
32. Milanes MV, Laorden ML, Chapleur-Chateau M, Burlet A (1998) Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal: correlation with hypothalamic noradrenergic activity and pituitary-adrenal response. J Pharmacol Exp Ther 285:700-706
33. Miller LG, Greenblatt DJ, Barnhill JG, Shader RI (1988) Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acid A receptor function. J Pharmacol Exp Ther 246:170-176
34. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa SI, Nakazato A, Kumagai T, Okubo T, Tomisawa K (1999) Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 289:926-935
35. Owens MJ, Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473
36. Owens MJ, Vargas MA, Knight DL, Nemeroff CB (1991) The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. J Pharmacol Exp Ther 258:349-356
37. Pich EM, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF, Weiss F (1995) Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15(8):5439-5447
38. Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993) Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605:25-32
39. Richter RM, Weiss F (1999) In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32:254-261
40. Roberts AJ, Crabbe JC, Keith LD (1992) Genetic differences in hypothalamic-pituitary-adrenal axis responsiveness to acute ethanol and acute ethanol withdrawal. Brain Res 579:296-302
41. Rodriguez de Fonseca F, Carrera MRA, Navarro M, Koob GF, Weiss F (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050-2054
42. Rohrer T, Von Richthofen V, Schulz C, Beyer J, Lehnert H (1994) The stress-, but not corticotropin-releasing hormone-induced activation of the pituitary-adrenal axis in man is blocked by alprazolam. Horm Metab Res 26:200-206
43. Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL (1992) Characteristics of long-term alprazolam users in the community. J Clin Psychopharmacol 12:316-332
44. Ryan GP, Boisse NR (1983) Experimental induction of benzodiazepine tolerance and physical dependence. J Pharmacol Exp Ther 226:100-107
45. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G (1995) Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 675:89-97
46. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD 3rd, Winston EN, Chen YL, Heym J (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 93:10477-10482
47. Skelton KH, Nemeroff CB, Knight DL, Owens MJ (2000) Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 20(3):1240-1248
48. Skutella T, Probst JC, Renner U, Holsboer F, Behl C (1998) Corticotropin-releasing hormone receptor (Type I) antisense targeting reduces anxiety. Neuroscience 85:795-805
49. Smith GW, Aubry J-M, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee K-F (1998) Corticotropin-releasing factor receptor 1-deficientmice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102
50. Stout SC, Owens MJ, Nemeroff CB (2002) Regulation of corticotropin- releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 300(3):1085-1092
51. Swerdlow NR, Geyer MA, Vale WW, Koob GF (1986) Corticotropin releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology 88:147-152
52. Thrivikraman KV, Nemeroff CB, Plotsky PM (2000) Sensitivity to glucocorticoid-mediated fast-feedback regulation of the hypothalamic-pituitary- adrenal axis is dependent upon stressor specific neurocircuitry. Brain Res 870(1-2):87-101
53. Thrivikraman KV, Huot RL, Plotsky PM (2002) Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. Brain Res Brain Res Protoc 10(2):84-94
54. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul J, Stalla G, Blanquet V, Steckler T, Holsboer F, Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nat Genet 19:162-166
55. Walberg L, Thrivikraman KV, Plotsky PM (2005) Combined pre- and postnatal environmental enrichment programs the HPA axis differentially in male and female rats. Psychoneuroendocrinology 31(5):553-564
56. Walton NY, Treiman DM (1990) Lorazepam treatment of experimental status epilepticus in the rat: relevance to clinical practice. Neurology 40(6):990-994
57. Zhou Y, Spangler R, Ho A, Kreek MJ (2003) Increased CRH mRNA levels in the rat amygdala during short-term withdrawal from chronic 'binge' cocaine. Brain Res Mol Brain Res 114(1):73-79
58. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high affinity corticotrophin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181